Navigation Links
New Pharmaceutical Company to Target Alzheimer's Disease
Date:10/21/2008

SARASOTA, Fla., Oct. 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease.

Archer Pharmaceuticals, Inc., led by Chief Executive Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer Fiona Crawford, Ph.D., was created based on the groundbreaking research that their team has been conducting in Florida for the past five years.

Archer Pharmaceuticals, Inc. has several compounds that are ready to enter clinical development, including ARC029 and ARC031. These compounds have been manufactured at the Sarasota-based facility to U.S. Food and Drug Administration (FDA) regulatory standards (GMP). Both are targeted at the reduction of soluble amyloid proteins in the brain -- thought by many to be the main culprits in degeneration of neurons in the brains of Alzheimer's disease sufferers. In addition, Archer Pharmaceuticals, Inc. has several other agents in the preclinical stage, including Gamma Secretase Inhibitors and BACE Inhibitors. These approaches are designed to attack the Alzheimer's disease soluble amyloid in different ways, providing complementary approaches to the lead compounds.

ARC029 was selected from approximately 2,000 agents as Archer Pharmaceuticals, Inc.'s first-line treatment for Alzheimer's because it was one of the most proficient at lowering amyloid levels in preclinical models. In these models ARC029 reduces brain amyloid levels by largely unexplored biological mechanisms.

"ARC029 acts to lower the soluble forms of amyloid before they damage the brain's neurons," said Dr. Mullan. "We believe that the soluble, rather than the deposited forms, are the real culprits in the disease, and so reducing them is our goal with this compound."

"Alzheimer's disease is a growing problem around the world, with devastating consequences for patients, caregivers and families," said Dr. Crawford. "We now have strategies to tackle the cause, not just the consequences, of Alzheimer's disease. We are confident that the expertise and dedication of the Archer staff will lead to effective treatments for this terrible disease."

A Phase I/IIA clinical trial, that is currently being conducted in Europe, was designed to evaluate the safety of Nilvadipine, the active ingredient of ARC029, in Alzheimer's sufferers. The study has shown that the drug was well tolerated in Alzheimer's patients.

While neither ARC029 nor ARC031 is currently available in the United States (U.S.), Archer Pharmaceuticals, Inc. is expecting to proceed with U.S. clinical studies within the next few months.

Archer Pharmaceuticals, Inc. intends to fast track ARC029 and ARC031, while continuing to work on other therapeutic approaches.

Archer Pharmaceuticals, Inc. is a fully independent health care company dedicated to enhancing and extending healthy human life. For more information or to invest in Archer Pharmaceuticals, Inc., please contact Geoff Birkett at (484) 467-1285 or visit http://www.ArcherPharma.com.


'/>"/>
SOURCE Archer Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
2. Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008
3. Anadys Pharmaceuticals to Present at BIOCOM Investor Conference 2008
4. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
5. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
6. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
7. Anadys Pharmaceuticals to Report Third Quarter 2008 Financial Results
8. Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008
9. Amylin Pharmaceuticals to Webcast Third Quarter Results
10. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
11. Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... VA (PRWEB) , ... February 06, 2016 , ... The ... session, cost-free, for middle and high school teachers on Wednesday February 10, 2016. ... held at the Smithsonian-Mason School of Conservation, located at 1500 Remount Road in Front ...
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
(Date:2/4/2016)... , February 4, 2016 ... a biotechnology acceleration company is pleased to provide the following ... --> Over the last 3 months we have ... securities purchase agreements exceeding $1,000,000. As a result, we have ... Mannin Research Inc. license agreement and expect that development to ...
Breaking Biology Technology:
(Date:2/5/2016)... DUBLIN , Feb. 5, 2016 /PRNewswire/ ... the addition of the "Global Facial ... offering. --> http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has ... Facial Recognition Market 2016-2020" report to ... Markets ( http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the ...
(Date:2/3/2016)... Calif. , Feb. 3, 2016 Vigilant ... Police Department in Missouri ... license plate reader (LPR) data from Vigilant Solutions. ... hit-and-run case in which the victim was walking out of a convenience ... parking space next to his vehicle, striking his vehicle ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):